Bio News
Labcorp will launch a direct-to-consumer (DTC) genetic test that analyzes 163 genes to predict the risk of more than 100 hereditary diseases. The test will provide information on genetic responses to certain medications, as well as risks for cancer, cardiovascular disease and other conditions, with the goal of detecting early genetic risks carried by one in six adults. Labcorp said about 90% of people are unaware of their risks, and the test is scheduled to become available Aug. 3.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
